Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Acusphere Secures Funding From Cephalon To See Imagify Through PDUFA

This article was originally published in The Pink Sheet Daily

Executive Summary

Cephalon gains option to license the cardiovascular imaging drug, as well as rights to an injectable formula of celecoxib in preclinical development.
Advertisement

Related Content

Acusphere Left Unstable By FDA Panel Review; CEO Turns Ire On Panelists
Acusphere Left Unstable By FDA Panel Review; CEO Turns Ire On Panelists
Acusphere’s Imagify Hit Hard With FDA Panel Rejection
Acusphere’s Imagify Hit Hard With FDA Panel Rejection
FDA Hints At Additional Trials for Acusphere’s Imagify
FDA Hints At Additional Trials for Acusphere’s Imagify

Topics

Advertisement
UsernamePublicRestriction

Register

PS066935

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel